SUNDAY, JUNE 24, 2018

Artificial virus may be key to Chikungunya vaccine

Artificial virus may be key to Chikungunya vaccine
Artificial virus may be key to Chikungunya vaccine | Courtesy of
Researchers from Paul-Ehrlich-Institut recently discovered that artificially made virus fragments may be instrumental to creating a vaccine for Chikungunya virus.

The Asian tiger mosquito is responsible for the transmission of Chikungunya virus, which is most commonly found in tropical and subtropical climates. It is continuously spreading and there is no vaccine to prevent the virus or treatment once it is contracted. The virus has already started epidemics in Southeast Asia, Africa, the Indian Ocean region, Central America, the Caribbean and South America. Experts also estimate that approximately 1.2 million people have been infected with Chikungunya in the U.S.

Recombined segments of the Chikungunya virus’s surface protein called E2 made artificial proteins that may provide protection from the virus when implemented into a small protein fragment vaccine.

"Our research work shows that single and artificially composed fragments of the Chikungunya virus surface protein may suffice to induce a partially protective immune response,” Paul-Ehrlich-Institut professor Barbara Shnierle said. “We consider our vaccine approach as promising for further development."

Organizations in this Story


Want to get notified whenever we write about Paul-Ehrlich-Institut ?
Next time we write about Paul-Ehrlich-Institut, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.